Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The inflammatory activation of microglia participates in dopaminergic neurodegeneration in PD. Therefore, chemicals that inhibit microglial activation are considered to have therapeutic potential for PD. Aromatic (ar)-turmerone is a main component of turmeric oil extracted from Curcuma longa and has anti-inflammatory activity in cultured microglia. The aims of the present study are (1) to investigate whether naturally occurring S-enantiomer of ar-turmerone (S-Tur) protects dopaminergic neurons in midbrain slice cultures and (2) to examine ar-turmerone analogs that have higher activities than S-Tur in inhibiting microglial activation and protecting dopaminergic neurons. R-enantiomer (R-Tur) and two analogs showed slightly higher anti-inflammatory effects in microglial BV2 cells. S- and R-Tur and these two analogs reversed dopaminergic neurodegeneration triggered by microglial activation in midbrain slice cultures. Unexpectedly, this neuroprotection was independent of the inhibition of microglial activation. Additionally, two analogs more potently inhibited dopaminergic neurodegeneration triggered by a neurotoxin, 1-methyl-4-phenylpyridinium, than S-Tur. Taken together, we identified two ar-turmerone analogs that directly and potently protected dopaminergic neurons. An investigation using dopaminergic neuronal precursor cells suggested the possible involvement of nuclear factor erythroid 2-related factor 2 in this neuroprotection.
Highlights
Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms, such as bradykinesia, resting tremor, and rigidity [1,2]
We have previously demonstrated that lipopolysaccharide (LPS) injection into substantia nigra pars compacta (SNpc) triggers microglial activation and dopaminergic neurodegeneration in mice [6]
We investigated the effects of these compounds on dopaminergic neurodegeneration triggered by 1-methyl-4-phenylpyridinium (MPP+), a neurotoxin that is specific for dopaminergic neurons and frequently used to establish PD models [2]
Summary
Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms, such as bradykinesia, resting tremor, and rigidity [1,2]. Dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain selectively and progressively degenerate in patients with PD [1,2,3]. It remains unknown how the dopaminergic neurons in the SNpc selectively degenerate in PD. We established an experimental model of inflammatory degeneration of dopaminergic neurons using midbrain slice cultures that are treated with interferon γ (IFNγ) and LPS to trigger microglial activation [7] and revealed that chemicals that inhibit microglial activation protect dopaminergic neurodegeneration [6,7,8]. The inflammatory activation of microglia is one of the key regulators of dopaminergic neurodegeneration in PD
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.